UTHR vs. IONS, ALKS, MDGL, FOLD, BMRN, ALNY, TEVA, RDY, JAZZ, and VTRS
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Madrigal Pharmaceuticals (MDGL), Amicus Therapeutics (FOLD), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), and Viatris (VTRS). These companies are all part of the "pharmaceutical preparations" industry.
United Therapeutics vs.
Ionis Pharmaceuticals (NASDAQ:IONS) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
Ionis Pharmaceuticals received 121 more outperform votes than United Therapeutics when rated by MarketBeat users. However, 60.77% of users gave United Therapeutics an outperform vote while only 60.66% of users gave Ionis Pharmaceuticals an outperform vote.
87.3% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 95.6% of United Therapeutics shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 12.4% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Ionis Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
United Therapeutics has a net margin of 37.56% compared to Ionis Pharmaceuticals' net margin of -45.75%. United Therapeutics' return on equity of 16.30% beat Ionis Pharmaceuticals' return on equity.
United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, United Therapeutics had 12 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 17 mentions for United Therapeutics and 5 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.45 beat United Therapeutics' score of 0.26 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.
Ionis Pharmaceuticals currently has a consensus target price of $45.17, suggesting a potential upside of 26.38%. United Therapeutics has a consensus target price of $291.55, suggesting a potential upside of 30.18%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Ionis Pharmaceuticals.
Summary
United Therapeutics beats Ionis Pharmaceuticals on 15 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
